IP Library › Granted Patent US 9,458,484
Granted Patent B2
US 9,458,484 · App. 13/277,763 · Granted Oct 4, 2016

Reverse transcriptase mixtures with improved storage stability

Inventors: Jason Ma (Hercules, CA); Xiao-Song Gong (Richmond, CA)
Assignee: Bio-Rad Laboratories, Inc.
C12P19/34C12N9/1276C12N9/96C12Y207/07049Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,458,484
App. No.
13/277,763
Granted
Oct 4, 2016
Kind
B2
Abstract

Reverse transcriptase mixtures with improved storage stability are provided.

Claims (15)

1. A frozen sterile aqueous reaction mixture comprising sufficient ingredients, except template RNA, for reverse transcription of RNA, the mixture comprising:

a reverse transcriptase having an optimal pH above 8;

deoxytriphosphate nucleotides; and

a buffer, wherein the buffer is selected from the group consisting of Tris, HEPES, ACES, PIPES, MOPSO, BES, MOPS, TES, TAPSO, POPSO, BICINE, TAPS, and AMPSO,

wherein said frozen sterile aqueous reaction mixture has a pH of between 6-8 and lacks template RNA.

2. The frozen sterile aqueous reaction mixture of claim 1 , wherein said buffer, when measured at a concentration of 0.1 M, has a change of no more than 0.027 pH units per degree Celsius when between 20° C. and 37° C.

3. The frozen sterile aqueous reaction mixture of claim 1 , further comprising one or more polyols having a total polyol concentration of at least 15%, wherein said polyol is a four or more carbon alcohol.

4. The frozen sterile aqueous reaction mixture of claim 3 , wherein said polyol is selected from the group consisting of sorbitol and xylitol.

5. The frozen sterile aqueous reaction mixture of claim 1 , wherein said reverse transcriptase is selected from the group consisting of murine leukemia virus (MLV) reverse transcriptase, Avian Myeloblastosis Virus (AMV) reverse transcriptase, Respiratory Syncytial Virus (RSV) reverse transcriptase, Equine Infectious Anemia Virus (EIAV) reverse transcriptase, Rous-associated Virus-2 (RAV2) reverse transcriptase, SUPERSCRIPT II reverse transcriptase, SUPERSCRIPT I reverse transcriptase, THERMOSCRIPT reverse transcriptase and MMLV RNase H-reverse transcriptase.

6. The frozen sterile aqueous reaction mixture of claim 1 , wherein said frozen sterile aqueous reaction mixture further comprises potassium chloride, magnesium, one or more detergents, an oligo dT, an oligonucleotide other than an oligo dT, an RNase inhibitor, or a combination thereof.

7. The frozen sterile aqueous reaction mixture of claim 1 , consisting of said reverse transcriptase, said buffer, potassium chloride, MgSO 4 , one or more polyol(s), EDTA, and oligonucleotides.

8. The frozen sterile aqueous reaction mixture of claim 1 , wherein said reverse transcriptase is selected from the group consisting of SUPERSCRIPT II reverse transcriptase, SUPERSCRIPT I reverse transcriptase, THERMOSCRIPT reverse transcriptase and MMLV RNase H-reverse transcriptase.

9. The frozen sterile aqueous reaction mixture of claim 1 , further comprising one or more detergents.

10. The frozen sterile aqueous reaction mixture of claim 1 , further comprising an oligo dT oligonucleotide.

11. The frozen sterile aqueous reaction mixture of claim 1 , wherein said buffer is at a concentration of between 100-500 mM.

Continuity (2)
Provisional Application 61405961 · Oct 22, 2010
Related Publication 20120129238A1 · May 24, 2012